Russell Investments Group Ltd. Buys 23,788 Shares of Integra LifeSciences Holdings Co. (NASDAQ:IART)

Russell Investments Group Ltd. boosted its holdings in Integra LifeSciences Holdings Co. (NASDAQ:IART - Free Report) by 28.0% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 108,890 shares of the life sciences company's stock after purchasing an additional 23,788 shares during the quarter. Russell Investments Group Ltd. owned about 0.14% of Integra LifeSciences worth $2,470,000 at the end of the most recent quarter.

Other hedge funds have also recently made changes to their positions in the company. ExodusPoint Capital Management LP bought a new stake in Integra LifeSciences during the fourth quarter valued at about $1,096,000. Villanova Investment Management Co LLC increased its holdings in Integra LifeSciences by 10.8% in the 4th quarter. Villanova Investment Management Co LLC now owns 43,224 shares of the life sciences company's stock worth $980,000 after acquiring an additional 4,217 shares in the last quarter. Headlands Technologies LLC bought a new stake in Integra LifeSciences during the 4th quarter worth approximately $271,000. Cannell & Spears LLC purchased a new position in Integra LifeSciences during the fourth quarter valued at approximately $3,555,000. Finally, Arrowstreet Capital Limited Partnership boosted its position in shares of Integra LifeSciences by 7.1% in the fourth quarter. Arrowstreet Capital Limited Partnership now owns 13,756 shares of the life sciences company's stock worth $312,000 after purchasing an additional 913 shares during the period. 84.78% of the stock is owned by institutional investors.

Integra LifeSciences Trading Up 3.7 %

NASDAQ:IART traded up $0.58 during mid-day trading on Wednesday, hitting $16.25. 290,849 shares of the stock traded hands, compared to its average volume of 1,039,734. The company has a quick ratio of 0.73, a current ratio of 1.20 and a debt-to-equity ratio of 0.79. Integra LifeSciences Holdings Co. has a 52 week low of $14.45 and a 52 week high of $32.66. The stock has a market capitalization of $1.25 billion, a price-to-earnings ratio of -180.09, a PEG ratio of 0.73 and a beta of 1.24. The firm's 50 day moving average is $20.95 and its two-hundred day moving average is $22.23.

Integra LifeSciences (NASDAQ:IART - Get Free Report) last issued its quarterly earnings results on Tuesday, February 25th. The life sciences company reported $0.97 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.85 by $0.12. Integra LifeSciences had a positive return on equity of 12.35% and a negative net margin of 0.42%. The firm had revenue of $442.65 million during the quarter, compared to analyst estimates of $445.15 million. During the same period last year, the company earned $0.89 EPS. Integra LifeSciences's quarterly revenue was up 11.5% compared to the same quarter last year. On average, equities research analysts predict that Integra LifeSciences Holdings Co. will post 2.45 earnings per share for the current year.

Analysts Set New Price Targets

A number of research analysts recently weighed in on the stock. Truist Financial lowered their target price on shares of Integra LifeSciences from $26.00 to $19.00 and set a "hold" rating on the stock in a research note on Friday, April 11th. Argus raised shares of Integra LifeSciences from a "hold" rating to a "buy" rating in a report on Monday, March 31st. Three research analysts have rated the stock with a sell rating, five have given a hold rating and two have issued a buy rating to the company. According to MarketBeat, the stock has an average rating of "Hold" and an average target price of $22.71.

Integra LifeSciences Company Profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.